MAM
SYRE icon

Meeder Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Meeder Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-181
Closed -$5.93K – 1010
2025
Q4 		$5.93K Sell
181
-35
-16% -$915 ﹤0.01% 772
2025
Q3 		$3.62K Buy
216
+46
+27% +$750 ﹤0.01% 719
2025
Q2 		$2.54K Buy
+170
New +$2.52K ﹤0.01% 799
2020
Q2 		– Sell
-9
Closed -$1K – 2450
2020
Q1 		$1K Sell
9
-39
-81% -$6.63K ﹤0.01% 2232
2019
Q4 		$10K Buy
48
+41
+586% +$8.05K ﹤0.01% 1568
2019
Q3 		$1K Sell
7
-6
-46% -$1.17K ﹤0.01% 2085
2019
Q2 		$2K Sell
13
-270
-95% -$46.7K ﹤0.01% 1880
2019
Q1 		$57K Buy
283
+78
+38% +$16.3K ﹤0.01% 843
2018
Q4 		$38K Buy
205
+64
+45% +$13.6K ﹤0.01% 888
2018
Q3 		$35K Buy
+141
New +$32.9K ﹤0.01% 886

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Meeder Asset Management's SYRE Position: Q1 2026 in Review

Meeder Asset Management sold out of Spyre Therapeutics (SYRE) in Q1 2026, closing a stake of 181 shares — an estimated $5.93K sold.

Meeder Asset Management first reported a position in SYRE in Q3 2018 and held it in 10 quarters. The position peaked at $57K in Q1 2019. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Meeder Asset Management reported no remaining Spyre Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Meeder Asset Management sold 181 Spyre Therapeutics shares in Q1 2026, an estimated $5.93K.
  • Meeder Asset Management first reported a position in Spyre Therapeutics in Q3 2018 and held it in 10 quarters.
  • Meeder Asset Management's Spyre Therapeutics position peaked at $57K in Q1 2019.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.